Alliances
In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.
A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
The U.S. FDA has approved Lynparza for the adjuvant treatment of patients diagnosed with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Bristol Myers Squibb and Nektar Therapeutics said their joint Phase III PIVOT IO-001 study did not meet two endpoints: progression-free survival and objective response rate.
Harpoon Therapeutics, Inc. has unfortunately announced that it will move to discontinue one of its promising T cell engager biologics, HPN424.
The two companies will work closely to harness the abilities of dopamine receptor modulators to help patients living with complex neuropsychiatric conditions.
PRESS RELEASES